Silence Therapeutics (SLN) Net Cash Flow (2020 - 2026)
Silence Therapeutics recorded quarterly Net Cash Flow of -$5.6 million in Q1 2026, up 92.07% quarter-over-quarter from -$70.6 million in Q4 2025, and up 90.12% year-over-year from -$2.9 million in Q1 2025.
Silence Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$5.6 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 90.12% year-over-year to -$5.6 million; the TTM figure through Mar 2026 stood at -$59.2 million (up 23.85% YoY), while the FY2025 annual figure was -$110.2 million, down 310.07% from the prior year.
- Net Cash Flow came in at -$5.6 million for Q1 2026 at Silence Therapeutics, up from -$70.6 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $74.0 million in Q1 2024 to a low of -$70.6 million in Q4 2025.
- A 5-year average of -$5.4 million and a median of -$9.6 million in 2023 frame the typical range for Net Cash Flow.
- On a YoY basis, Net Cash Flow climbed as much as 16706.5% in 2022 and fell as far as 1253.11% in 2022.
- Silence Therapeutics' Net Cash Flow stood at -$34.9 million in 2022, then soared by 72.37% to -$9.6 million in 2023, then surged by 499.44% to $38.5 million in 2024, then slumped by 283.18% to -$70.6 million in 2025, then jumped by 92.07% to -$5.6 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$5.6 million, -$70.6 million, and $40.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Silence Therapeutics | 924.61 Mn | 854.53 Mn | 411,000.00 | -5.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.60 Mn |
| Mar 31, 2026 | -5.60 Mn |
| Dec 31, 2025 | -70.61 Mn |
| Dec 31, 2025 | -70.61 Mn |
| Sep 30, 2025 | 40.38 Mn |
| Sep 30, 2025 | 40.38 Mn |
| Jun 30, 2025 | -23.35 Mn |
| Jun 30, 2025 | -23.35 Mn |
| Mar 31, 2025 | -56.68 Mn |
| Mar 31, 2025 | -56.68 Mn |
| Dec 31, 2024 | 38.55 Mn |
| Dec 31, 2024 | 38.55 Mn |
| Sep 30, 2024 | -55.26 Mn |
| Sep 30, 2024 | -55.26 Mn |
| Jun 30, 2024 | -4.32 Mn |
| Jun 30, 2024 | -4.32 Mn |
| Mar 31, 2024 | 73.97 Mn |
| Mar 31, 2024 | 73.97 Mn |
| Dec 31, 2023 | -9.65 Mn |
| Dec 31, 2023 | -9.65 Mn |
| Sep 30, 2023 | 35.20 Mn |
| Sep 30, 2023 | 35.20 Mn |
| Jun 30, 2023 | -20.62 Mn |
| Jun 30, 2023 | -20.62 Mn |
| Mar 31, 2023 | -9.13 Mn |
| Mar 31, 2023 | -9.13 Mn |
| Dec 31, 2022 | -34.93 Mn |
| Dec 31, 2022 | -34.93 Mn |
| Sep 30, 2022 | 39.62 Mn |
| Sep 30, 2022 | 39.62 Mn |
| Jun 30, 2022 | -10.47 Mn |
| Jun 30, 2022 | -10.47 Mn |
| Mar 31, 2022 | -19.42 Mn |
| Mar 31, 2022 | -19.42 Mn |
| Dec 31, 2021 | 3.03 Mn |
| Dec 31, 2021 | 3.03 Mn |
| Sep 30, 2021 | 235,737.75 |
| Sep 30, 2021 | 235,737.75 |
| Jun 30, 2021 | 35.69 Mn |
| Jun 30, 2021 | 35.69 Mn |
| Mar 31, 2021 | 25.15 Mn |
| Mar 31, 2021 | 25.15 Mn |
| Dec 31, 2020 | 19.09 Mn |
| Dec 31, 2020 | 19.09 Mn |
| Sep 30, 2020 | 4.90 Mn |
| Sep 30, 2020 | 4.90 Mn |